Brussels, 25/09/2006 (Agence Europe) - Following the parliamentary committee's rejection of the Mikolasik report (EUROPE 9266), it is highly unlikely that the European Parliament will be able to conclude its first reading of the draft regulation on the authorisation of innovative therapies before February 2007. The main patient associations and the pharmaceutical industry, represented by the European Biopharmaceutical Enterprises (EBE), deplores this additional delay. Although some people...